SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

"The next phase for Miami will be an increase in exits"

"There is nothing that Israeli high-tech cannot withstand"

"We see the biggest opportunities in residential construction"

"Our goal is to produce clean, affordable energy that supports the economy"

Buzz

Most popular

Daily

Weekly

1

Oracle CEO: "If we continue on our current trajectory, reaching a valuation of a trillion dollars is inevitable"

2

Is your solitaire opponent actually a bot?

3

Once $5 billion IPO bound, Cybereason merges with Trustwave amid decline

4

"The next phase for Miami will be an increase in exits"

5

Cloudera acquires Israeli startup Octopai to advance metadata and AI integration

Nasdaq

20 stories about Nasdaq

קולפלנט דיו ביולוגי

Global Licensing and Commercialization Deal Catapults Collplant on Nasdaq

22.10.18|Lilach Baumer

The tissue regeneration company announced on Monday a deal with biotech company United Therapeutics and is currently up over 60% in pre-market trading

נאסד"ק וול סטריט

Novartis-Backed Gamida Downgrades Nasdaq IPO Expectations to $50-$60 Million

18.10.18|Lilach Baumer

The Jerusalem-based biotech company filed for a $69 million initial public offering in September but disclosed no pricing terms

נאסד"ק וול סטריט

Biotech Company Gamida Cell Files for $69 Million Nasdaq IPO

30.09.18|Dror Reich

The Jerusalem-based company develops cellular and immune therapies. Its lead product is a universal bone marrow transplant solution

Nasdaq-Listed Diabetes Monitoring Company Dario Raises $10.3 Million in Private Placement

Israel-headquartered Dario develops a diabetes monitoring device that lets users test and track their blood-glucose levels using a smartphone

נאסדק נאסד"ק ניו יורק בורסה בועה

Barclays Sees Potential Upside in Nice Stock Following Second-Quarter Reports

On Thursday, Israel-headquartered Nice reported GAAP revenues of $342 million, a 10% increase year-over-year, bolstered by a 28% year-over-year increase in cloud revenues

נאסד"ק וול סטריט

RedHill’s Clinical Trial Results Undermine Its Underwritten Offering

12.08.18|Dror Reich

The gastro treatment company announced a successful Crohn's disease treatment trial two weeks ago. While investors initially seemed hyped, successful trials from competitors brought RedHill’s stock down since

פאנל סולארי אנרגיה מתחדשת

SolarEdge Extends Patents Lawsuit Against Huawei

01.08.18|Amarelle Wenkert

The solar energy company has a pending lawsuit in Germany against the Chinese telecommunications company and a German distributor

Gastro Treatment Company RedHill Jumps on Nasdaq Following Successful Clinical Trial

30.07.18|Lilach Baumer

The Tel Aviv-headquartered company stated its Crohn's disease treatment trial met its primary endpoint and key secondary endpoints

נאסדק נאסד"ק ניו יורק בורסה בועה

Surveillance Company Ability Looking to Raise Up to $50 Million in Shelf Offering

Earlier this month, the Tel Aviv-based company announced it has received a delisting determination from Nasdaq

In Pivot, AudioCodes to Pay Out Dividends

25.07.18|Dror Reich

Revenue grew 12.3 percent to $43.5 million compared to the second quarter of last year

נאסדק נאסד"ק ניו יורק בורסה בועה

Wix.com Reports Higher Revenue and Improved Yearly Forecast

25.07.18|Asaf Shalev

The provider of website building tools also said it turned a profit in the second quarter excluding one-time items

מנכ"ל מדיגוס כריס רולנד

Medical Device Company Medigus Raises $10 Million in Public Offering

Medigus develops minimally invasive endosurgical tools and direct visualization technology

נאסד"ק וול סטריט

Gastro Treatment Company RedHill Wants to Raise $117 on Nasdaq

24.07.18|Lilach Baumer

The Tel Aviv-headquartered company announced on Monday that Nasdaq approved its listing on its second tier, the Global Market. RedHill's ADSs were previously listed on Nasdaq Capital Market

נאסד"ק וול סטריט

Nasdaq Sends Notice of Delisting to Interception Company Ability

Last week, Tel Aviv-based Ability announced the SEC is considering disciplinary action against it in connection to a 2015 merger, and to business information filed by the company

Sustained Drug Release Company UroGen Submits New Drug Application to FDA

12.07.18|Amir Rosenbaum

Kite Pharma founder Arie Belldegrun is the chairman of Israel-based UroGen, which focuses mainly on cancer treatment and urinary tract infections

נאסד"ק וול סטריט

Oral Insulin Capsule Developer Oramed Raises $18 Million in Direct Offering

Jerusalem-headquartered Oramed intends to use the recent proceeds for research and development and for clinical trials

נאסדק נאסד"ק ניו יורק בורסה בועה

SEC Considering Disciplinary Action Against Interception Company Ability

09.07.18|Dror Reich

Tel Aviv-based Ability has been under probe since February 2017 in regards to a 2015 merger, and to business information filed by the company

נאסד"ק וול סטריט

Cybersecurity Company Safe-T Group Submits Preliminary Prospectus for Nasdaq IPO

08.07.18|Lilach Baumer

The company is currently listed on the Tel Aviv Stock Exchange and on the OTCQB venture market

נאסד"ק וול סטריט

Fourth Time’s the Charm for Entera Bio IPO

01.07.18|Dror Reich

The Israel-based oral drug developer listed on Nasdaq on Thursday, pricing 1.4 million units of one share and one warrant at $8 each

פרופסור קרין נהון נשיאת איגוד האינטרנט

CTech's Monday Roundup of Israeli Tech News

Israeli civil liberties groups warn against potential for abuse in cybersecurity bill. After hitting new low, surveillance company Ability jumps on Nasdaq

Previous Articles More Articles